Intralesional corticosteroid therapy for primary cutaneous B-cell lymphoma

Perry, Adam; Vincent, Bini; Parker, Sareeta

doi:10.1111/j.1365-2133.2010.09798.x

Cited by 28 publications

(19 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Topical therapies such as high-potency steroids, imiquimod, nitrogen mustard, and bexarotene and IL steroids[73] seem to have some success in selected, symptomatic patients. [4474]…”

Section: Primary Cutaneous Follicle Center Lymphomamentioning

confidence: 99%

A literature revision in primary cutaneous B-cell lymphoma

et al. 2017

View full text Add to dashboard Cite

The term “Primary Cutaneous B-Cell Lymphoma” (PCBCL) comprehends a variety of lymphoproliferative disorders characterized by a clonal proliferation of B-cells primarily involving the skin. The absence of evident extra-cutaneous disease must be confirmed after six-month follow-up in order to exclude a nodal non-Hodgkin's lymphoma (NHL) with secondary cutaneous involvement, which may have a completely different clinical behavior and prognosis. In this article, we have summarized the clinico-pathological features of main types of PCBCL and we outline the guidelines for management based on a review of the available literature.

show abstract

“…Topical therapies such as high-potency steroids, imiquimod, nitrogen mustard, and bexarotene and IL steroids[73] seem to have some success in selected, symptomatic patients. [4474]…”

Section: Primary Cutaneous Follicle Center Lymphomamentioning

confidence: 99%

A literature revision in primary cutaneous B-cell lymphoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Therefore, complete excision alone, deferring radiation until disease recurrence, is also reasonable. Intralesional (e.g., corticosteroids) or topical therapies may also be considered [28,29]. While radiation therapy is generally recommended for patients with a solitary lesion, radiation therapy or observation (i.e., "watch and wait") are reasonable options for those patients with multiple lesions.…”

Section: Pcfclmentioning

confidence: 99%

Cutaneous B‐cell lymphomas: 2016 update on diagnosis, risk‐stratification, and management

Wilcox

2016

American J Hematol

View full text Add to dashboard Cite

Disease overviewApproximately one‐fourth of cutaneous lymphomas are B‐cell derived and are generally classified into three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL, LT).DiagnosisDiagnosis and disease classification is based on histologic review and immunohistochemical staining of an appropriate skin biopsy. Pathologic review and an appropriate staging evaluation are necessary to distinguish primary cutaneous B‐cell lymphomas from systemic B‐cell lymphomas with secondary skin involvement.Risk‐stratificationDisease histology remains the most important prognostic determinant. Both PCFCL and PCMZL are indolent lymphomas that infrequently disseminate to extracutaneous sites and are associated with 5‐year survival rates that exceed 95%. In contrast, PCDLBCL, LT is an aggressive lymphoma with an inferior prognosis.Risk‐adapted therapyPCFCL and PCMZL patients with solitary or relatively few skin lesions may be affectively managed with local radiation therapy. While single‐agent rituximab may be employed for patients with more widespread skin involvement, multiagent chemotherapy is rarely appropriate. In contrast, management of patients with PCDLBCL, LT is comparable to the management of patients with systemic DLBCL. Am. J. Hematol. 91:1052–1055, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

“…Although pcBCLs are skin-limited and rarely demonstrate extracutaneous spread, 1 they can be distressing to patients and disfiguring. Common local therapies include intralesional steroid injection, topical steroids, 2 and excision. 3 Steroid injections induce a durable complete remission in only 44% of patients and may require multiple rounds of injections; topical steroids are typically ineffective.…”

Section: To the Editormentioning

confidence: 99%

“…3 Steroid injections induce a durable complete remission in only 44% of patients and may require multiple rounds of injections; topical steroids are typically ineffective. 2 Excision can be definitive, but these lymphomas have a strong propensity for local recurrence, making field therapy preferable. Locoregional radiation therapy (RT) is an alluring option with significantly higher complete remission rates.…”

Section: To the Editormentioning

confidence: 99%